Inhibrx Biosciences, Inc. (INBX)
Data as of , from SEC Form 4 filings.
Net insider buying (90d)Watch INBX
See up to 3 months of INBX. The 7-day demo opens the 1M and 3M ranges and puts INBX on your watchlist.
Start 7-day demoLatest INBX insider trades
About Inhibrx Biosciences, Inc. (INBX)
Inhibrx Biosciences, Inc. is an SEC registrant, filing under CIK 0002007919, classified as biological products (no diagnostic substances). We track it alongside the rest of the Health Care sector.
INBX Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 14 | 52,500 | $5.50M |
| Open-market sale | 5 | 2,500 | $279K |
| Grant or award | 4 | 40,000 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
INBX insider transactions (Form 4)
4224 Form 4 filings on record, the earliest from Oct 7, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mark Lappe - Officer | Open-market purchase | Common Stock | 3,324 | $98.87 footnote F1 | $329K | |
| Mark Lappe - Officer | Open-market purchase | Common Stock | 2,176 | $99.60 footnote F3 | $217K | |
| Mark Lappe - Officer | Open-market purchase | Common Stock | 1,500 | $98.88 footnote F4 | $148K | |
| Mark Lappe - Officer | Open-market purchase | Common Stock | 3,000 | $101.70 footnote F5 | $305K | |
| ||||||
| Jon Faiz Kayyem - Director | Open-market purchase | Common Stock | 5,000 | $100.00 | $500K | |
| Douglas Forsyth - Director | Grant or award | Stock Option (right to buy) | 10,000 | $0.00 | - | |
| Kristiina Md Vuori - Director | Grant or award | Stock Option (right to buy) | 10,000 | $0.00 | - | |
| Kimberly Manhard - Director | Grant or award | Stock Option (right to buy) | 10,000 | $0.00 | - | |
| Jon Faiz Kayyem - Director | Grant or award | Stock Option (right to buy) | 10,000 | $0.00 | - | |
| Jon Faiz Kayyem - Director | Open-market purchase | Common Stock | 5,000 | $100.00 | $500K | |
| Kimberly Manhard - Director | Open-market sale | Common Stock | 500 | $111.78 | $56K | |
| Kimberly Manhard - Director | Open-market sale | Common Stock | 500 | $110.26 | $55K | |
| Kimberly Manhard - Director | Open-market sale | Common Stock | 500 | $105.05 | $53K | |
| Kimberly Manhard - Director | Open-market sale | Common Stock | 500 | $115.14 | $58K | |
| Kimberly Manhard - Director | Open-market sale | Common Stock | 500 | $115.80 | $58K | |
| Jon Faiz Kayyem - Director | Open-market purchase | Common Stock | 5,000 | $113.52 footnote F1 | $568K | |
| ||||||
| Douglas Forsyth - Director | Open-market purchase | Common Stock | 2,500 | $114.65 footnote F1 | $287K | |
| ||||||
| Mark Lappe - Officer | Open-market purchase | Common Stock | 5,895 | $99.29 footnote F1 | $585K | |
| Mark Lappe - Officer | Open-market purchase | Common Stock | 6,605 | $100.64 footnote F3 | $665K | |
| Mark Lappe - Officer | Open-market purchase | Common Stock | 1,100 | $107.12 footnote F4 | $118K | |
| Mark Lappe - Officer | Open-market purchase | Common Stock | 500 | $108.24 footnote F5 | $54K | |
| Mark Lappe - Officer | Open-market purchase | Common Stock | 1,219 | $111.88 footnote F6 | $136K | |
| Mark Lappe - Officer | Open-market purchase | Common Stock | 9,681 | $112.28 footnote F7 | $1.09M | |
| ||||||
| Kristiina Md Vuori - Director | Grant or award | Stock Option (right to buy) | 15,000 | $0.00 | - | |
| Jon Faiz Kayyem - Director | Grant or award | Stock Option (right to buy) | 15,000 | $0.00 | - | |
| Douglas Forsyth - Director | Grant or award | Stock Option (right to buy) | 15,000 | $0.00 | - | |
| Kimberly Manhard - Director | Grant or award | Stock Option (right to buy) | 15,000 | $0.00 | - | |
 David Matly - Officer | Grant or award | Stock Option (right to buy) | 50,000 | $0.00 | - | |
| VIKING GLOBAL INVESTORS LP | Open-market sale | Common Stock | 308,643 | $32.25 | $9.95M | |
| VIKING GLOBAL INVESTORS LP | Open-market sale | Common Stock | 16,315 | $32.25 | $526K | |
| VIKING GLOBAL INVESTORS LP | Open-market sale | Common Stock | 25,042 | $32.25 | $808K | |
| Douglas Forsyth - Director | Grant or award | Stock Option (right to buy) | 15,000 | $0.00 | - | |
| Kimberly Manhard - Director | Grant or award | Stock Option (right to buy) | 15,000 | $0.00 | - | |
| Jon Faiz Kayyem - Director | Gift | Common Stock | 500,000 | $0.00 | - | |
| Jon Faiz Kayyem - Director | Gift | Common Stock | 250,000 | $0.00 | - | |
| Jon Faiz Kayyem - Director | Gift | Common Stock | 250,000 | $0.00 | - | |
| Jon Faiz Kayyem - Director | Gift | Common Stock | 52,000 | $0.00 | - | |
| Jon Faiz Kayyem - Director | Open-market purchase | Common Stock | 34,843 | $14.23 | $496K | |
| Jon Faiz Kayyem - Director | Open-market purchase | Common Stock | 34,843 | $14.23 | $496K | |
| Jon Faiz Kayyem - Director | Open-market purchase | Common Stock | 18,750 | $14.19 | $266K | |
| Jon Faiz Kayyem - Director | Open-market purchase | Common Stock | 18,750 | $14.19 | $266K | |
| Kristiina Md Vuori - Director | Open-market purchase | Common Stock | 6,667 | $15.00 | $100K | |
Item 7.01, 9.01
Item 7.01, 8.01, 9.01
Item 2.02, 9.01
Item 1.01, 2.03, 3.02, 7.01, 9.01
Recent INBX Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| MANHARD KIMBERLY | Director | 500 | $53K | View on EDGAR | |
| MANHARD KIMBERLY | Director | 500 | $55K |
INBX insider trading FAQ
What is the latest insider trade for INBX?
Inhibrx Biosciences, Inc. (INBX) had 12 insider filings in the last 90 days, with the most recent on 2026-09-28. The full record for INBX runs to 24 Form 4 filings, the earliest from 2024-10-07. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying INBX stock?
14 insider purchases of INBX were filed in the last 90 days, totaling $5.50M.
How many insiders are selling INBX stock?
5 insider sales of INBX were filed in the last 90 days, totaling $279K.
Where can I see INBX SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects INBX Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Mark Lappe view on EDGAR
- - Jon Faiz Kayyem view on EDGAR
- - Douglas Forsyth view on EDGAR
- - Kristiina Md Vuori view on EDGAR
- - Kimberly Manhard view on EDGAR
- - Jon Faiz Kayyem view on EDGAR
- - Jon Faiz Kayyem view on EDGAR
- - Kimberly Manhard view on EDGAR
- - Kimberly Manhard view on EDGAR
Related companies with recent insider activity
Learn more
- How to read insider buying signals
- What an open-market purchase by an insider can and cannot tell you.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where INBX's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow INBX with a 7-day demo
- INBX on your watchlist
- Every INBX Form 4 filing on record
- Up to 3 months of INBX price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
